{
    "id": 8864,
    "name": "acute monocytic leukemia",
    "source": "DOID",
    "definition": "A monocytic leukemia where the majority of monocytic cells are promonocytes. [url:https\\://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&version=18.09d&ns=ncit&code=C4861]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "9208"
    ],
    "termId": "DOID:8864",
    "evidence": [
        {
            "id": 11680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EDO-S101 and Kyprolis (carfilzomib) worked synergistically to decrease viability of an acute monocytic leukemia cell line in culture (PMID: 28753594).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6106,
                "therapyName": "Carfilzomib + Tinostamustine",
                "synonyms": null
            },
            "indication": {
                "id": 8864,
                "name": "acute monocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9700,
                    "pubMedId": 28753594,
                    "title": "The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28753594"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EDO-S101 and Velcade (bortezomib) worked synergistically to decrease viability of an acute monocytic leukemia cell line in culture (PMID: 28753594).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6105,
                "therapyName": "Bortezomib + Tinostamustine",
                "synonyms": null
            },
            "indication": {
                "id": 8864,
                "name": "acute monocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9700,
                    "pubMedId": 28753594,
                    "title": "The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28753594"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01627041",
            "title": "Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1739,
                    "therapyName": "Cytarabine + Daunorubicin + Decitabine",
                    "synonyms": null
                },
                {
                    "id": 1738,
                    "therapyName": "Cytarabine + Daunorubicin",
                    "synonyms": null
                }
            ]
        }
    ]
}